[HTML] sciencedirect.com

[HTML][HTML] Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

N Colombo, K Moore, G Scambia, A Oaknin… - Gynecologic …, 2021 - Elsevier
Objectives In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a
substantial progression-free survival benefit in patients with newly diagnosed, advanced …
被引用次数：25 相关文章

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

N Colombo, K Moore, G Scambia… - Gynecologic …, 2021 - pubmed.ncbi.nlm.nih.gov
Objectives In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a
substantial progression-free survival benefit in patients with newly diagnosed, advanced …

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

N Colombo, K Moore, G Scambia… - Gynecologic …, 2021 - gynecologiconcology-online.net
Objectives In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a
substantial progression-free survival benefit in patients with newly diagnosed, advanced …

[引用][C] Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

N Colombo, K Moore, G Scambia, A Oaknin… - Gynecologic …, 2021 - elibrary.ru
[PDF] ed.ac.uk

[PDF][PDF] Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

N Colombo, K Moore, G Scambia, A Oaknin… - pure.ed.ac.uk
• Detailed safety data from the SOLO1 trial of maintenance olaparib in newly diagnosed,
advanced BRCA-mutated ovarian cancer.• Maintenance olaparib had a predictable …
[HTML] nih.gov

[HTML][HTML] Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

N Colombo, K Moore, G Scambia, A Oaknin… - Gynecologic …, 2021 - ncbi.nlm.nih.gov
Objectives. In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a
substantial progression-free survival benefit in patients with newly diagnosed, advanced …
[PDF] archive.org

[PDF][PDF] Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

N Colombo, K Moore, G Scambia, A Oaknin… - scholar.archive.org
• Detailed safety data from the SOLO1 trial of maintenance olaparib in newly diagnosed,
advanced BRCA-mutated ovarian cancer.• Maintenance olaparib had a predictable …

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.

N Colombo, K Moore, G Scambia, A Oaknin… - Gynecologic …, 2021 - europepmc.org
Objectives In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a
substantial progression-free survival benefit in patients with newly diagnosed, advanced …

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

N Colombo, K Moore, G Scambia, A Oaknin… - GYNECOLOGIC …, 2021 - boa.unimib.it
Objectives: In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a
substantial progression-free survival benefit in patients with newly diagnosed, advanced …

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

N Colombo, K Moore, G Scambia, A Oaknin… - Gynecologic …, 2021 - research.ed.ac.uk
Objectives: In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a
substantial progression-free survival benefit in patients with newly diagnosed, advanced …